Approved indications: Elahere is FDA-approved as a single-agent treatment for adults with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1 to 3 prior systemic treatment regimens, selected using an FDA-approved FRα test.

Off-label uses: Use outside this setting is mainly within clinical trials (such as earlier treatment lines or combinations with other drugs); routine off-label prescribing in other cancers or in platinum-sensitive disease is not established and should generally be limited to research settings.

Efficacy expectations:

• In a large phase 3 trial in FRα-positive, platinum-resistant disease, Elahere improved outcomes compared with standard single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan), with higher response rates (about 4 in 10 vs about 1–2 in 10 patients), longer progression-free survival (by roughly 1–2 months), and longer overall survival (median about 16.5 vs 12.7 months).
• Tumor shrinkage or disease control is typically assessed after 2–3 cycles (around 6–9 weeks); some people experience durable benefit for many months, while others may not respond or may progress early.
• Effectiveness depends on how strongly the tumor expresses FRα, prior treatments, overall health, and how long treatment can be continued without unacceptable side effects.

Typical dosing and how it is given: For adults with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, the usual dose is 6 mg/kg based on adjusted ideal body weight (AIBW), given as an intravenous infusion once every 3 weeks (21-day cycle) in an infusion center or hospital, and continued until the cancer progresses or side effects become unacceptable.

Administration details: Elahere is prepared by oncology staff, diluted only in 5% dextrose (not saline), and infused through a vein or port using a special in-line filter. The first infusion is started slowly and, if tolerated, the rate is gradually increased; later infusions may be given more quickly up to the maximum recommended rate. Because it is an IV medicine, there are no requirements about taking it with food.

Premedications and eye care: Before each infusion, patients typically receive medicines such as a corticosteroid, antihistamine, antipyretic (for fever), and an anti-nausea drug to reduce infusion reactions and stomach upset. Regular eye exams are required, and patients are usually prescribed lubricating eye drops and steroid eye drops to use around each treatment cycle to help prevent or lessen eye toxicity.

Special dosing instructions and adjustments: If significant side effects occur, the oncology team may delay a dose, reduce the dose to 5 mg/kg or then 4 mg/kg AIBW, or permanently stop treatment if toxicity remains severe or recurs despite dose reductions. Dose adjustments are guided by the type and severity of problems such as eye findings, lung symptoms, neuropathy, blood counts, or liver test abnormalities.

Missed dose guidance: If a treatment appointment is missed or delayed, patients should contact their oncology clinic as soon as possible to reschedule; the team will adjust the infusion date and future cycle timing as needed rather than trying to "make up" a dose on their own.

Overdose: Overdose is unlikely because Elahere is given by healthcare professionals, but if too much is given, management is supportive—close monitoring for worsened side effects (especially eye problems, lung symptoms, blood count changes, or liver test elevations) and treatment of any complications.

Common side effects (frequency, onset, severity):

• Eye problems such as blurred vision, dry eye, sensitivity to light, eye pain, or changes seen on eye exam (keratopathy) are very common, often appearing within the first 1–2 months; they range from mild irritation to more significant vision changes but are often reversible with dose changes and eye treatments.
• Fatigue and weakness are common and can be mild to moderate, sometimes affecting daily activities, especially on treatment days or shortly afterward.
• Digestive symptoms including nausea, vomiting, diarrhea, constipation, and abdominal pain are common and usually manageable with diet changes and medicines.
• Liver test elevations (AST, ALT, alkaline phosphatase) and blood count changes (low white cells, platelets, or hemoglobin, low magnesium or albumin) are common and usually found on routine blood tests; they are often mild to moderate but sometimes require dose adjustments.
• Peripheral neuropathy (numbness, tingling, burning, or weakness in hands and feet) and musculoskeletal pain (muscle or joint aches) can develop over weeks to months and may be persistent if severe.

Serious or rare adverse effects requiring immediate medical attention:

• Severe ocular toxicity such as marked vision loss, severe eye pain, corneal ulcers, or uveitis (eye inflammation) needs urgent ophthalmology evaluation and often holding or stopping Elahere.
• Pneumonitis/interstitial lung disease may present with new or worsening cough, chest pain, shortness of breath, or low oxygen; this can be life-threatening and usually requires stopping the drug and prompt treatment.
• Severe infusion reactions or allergic reactions (fever, chills, rash, trouble breathing, swelling of face or throat) typically occur during or soon after the infusion and require stopping the infusion and emergency care.
• Severe neuropathy with significant weakness, pain, or functional loss can lead to permanent discontinuation of therapy.

Warnings and precautions (special populations and conditions): Elahere carries a boxed warning for ocular toxicity, so baseline and regular eye exams are required, and patients are advised not to wear contact lenses unless an eye specialist approves. Pneumonitis and peripheral neuropathy require close monitoring and dose changes if symptoms appear. Because Elahere can harm an unborn baby, effective contraception is needed during treatment and for 7 months after the last dose, and it should not be used during pregnancy. Breastfeeding is not recommended during treatment and for 1 month after the last dose. Use in children has not been established. No dose adjustment is recommended for mild hepatic or mild-to-moderate renal impairment, but the drug should generally be avoided in moderate or severe hepatic impairment; older adults (65+) have shown similar benefit and safety profiles but may have slightly more high-grade side effects and still require careful monitoring.

Safety compared with other treatments: Compared with standard single-agent chemotherapies used for platinum-resistant ovarian cancer, Elahere tends to cause distinctive eye-related side effects and still carries risks of neuropathy, lung inflammation, and blood count changes, but may have a different balance of toxicities that some patients find more tolerable than traditional chemotherapy.

How to report side effects and find safety updates: Patients and caregivers can report suspected side effects to the prescribing team, to the drug manufacturer’s patient support line, or directly to the U.S. FDA through the MedWatch program (by phone or online). Up-to-date safety information, including any new warnings or precautions, is posted on the FDA’s drug safety pages and in updated prescribing information for Elahere.

Drug and supplement interactions: The chemotherapy payload (DM4) in Elahere is broken down in the body mainly by the enzyme CYP3A4, so strong CYP3A4 inhibitors (for example, certain antifungal drugs, some antibiotics, and some HIV or hepatitis C medicines) can raise DM4 exposure and increase the risk of side effects; when these drugs are unavoidable, the oncology team will monitor more closely and may adjust treatment. There are no well-defined interactions with most common over-the-counter medicines or supplements, but patients should always provide a full list of all prescriptions, OTC products, herbal remedies, and vitamins so the oncology team and pharmacist can check for concerns.

Food, alcohol, and procedures: Because Elahere is given by IV, there are no specific food interactions, and it does not have known interactions with imaging contrast agents; however, heavy alcohol use can stress the liver and may worsen liver-related side effects, so moderation or avoidance is usually advised. Before surgeries or invasive procedures, the treating physicians will coordinate timing of Elahere doses and lab checks.

Conditions and co-medications that require caution: Extra care is needed in people with pre-existing eye disease, prior serious lung disease (which may increase pneumonitis risk), significant neuropathy, or liver disease. Elahere should generally be avoided in moderate to severe hepatic impairment, and is used with monitoring in mild hepatic or mild-to-moderate renal impairment. Patients receiving other drugs that can harm the eyes, lungs, nerves, or liver need especially close follow-up when Elahere is added.

Monitoring needs: Recommended monitoring includes baseline and periodic complete blood counts, liver function tests, and kidney function tests; regular ophthalmologic exams (before starting, every other cycle for the first several cycles, and as needed if symptoms arise); and clinical checks for respiratory symptoms, neuropathy, and infusion reactions at each visit. These tests help guide dose adjustments and decisions about holding or discontinuing treatment.

Q: What does Elahere treat?
A: Elahere is used to treat adults with folate receptor-alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already received 1 to 3 prior systemic treatments and whose tumors test positive for FRα.

Q: How often will I receive Elahere and how long does treatment last?
A: Elahere is typically given as an IV infusion once every 3 weeks, and treatment continues as long as it is helping control the cancer and side effects remain manageable.

Q: When might I notice whether Elahere is working?
A: Doctors usually perform scans and blood tests after about 2–3 treatment cycles (roughly 6–9 weeks) to see if tumors are shrinking, stable, or growing, and they use these results plus your symptoms to judge benefit.

Q: What eye symptoms should I watch for while on Elahere?
A: Let your care team know right away if you notice blurred vision, dry or gritty eyes, eye pain, redness, sensitivity to light, or any sudden change in vision, because these may signal eye toxicity that often improves with prompt treatment changes.

Q: Can I become pregnant or breastfeed while receiving Elahere?
A: Elahere can harm an unborn baby, so effective birth control is needed during treatment and for 7 months after the last dose, and breastfeeding is not recommended during treatment and for 1 month after the final dose.